Rua Life Sciences PLC (LSE:RUA) — Market Cap & Net Worth
Market Cap & Net Worth: Rua Life Sciences PLC (RUA)
Rua Life Sciences PLC (LSE:RUA) has a market capitalization of $147.24K (GBX1.21 Billion) as of May 5, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30891 globally and #1055 in its home market, demonstrating a 6.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rua Life Sciences PLC's stock price GBX19.50 by its total outstanding shares 62060272 (62.06 Million). Analyse Rua Life Sciences PLC cash flow conversion to see how efficiently the company converts income to cash.
Rua Life Sciences PLC Market Cap History: 2015 to 2026
Rua Life Sciences PLC's market capitalization history from 2015 to 2026. Data shows change from $203.88K to $147.24K (-6.02% CAGR).
Index Memberships
Rua Life Sciences PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.14 Million | 0.02% | #321 of 722 |
Weight: Rua Life Sciences PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rua Life Sciences PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rua Life Sciences PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Rua Life Sciences PLC's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
105.71x
Rua Life Sciences PLC's market cap is 105.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $151.02K | $625.56K | -$419.36K | 0.24x | N/A |
| 2017 | $320.91K | $490.03K | -$189.15K | 0.65x | N/A |
| 2018 | $373.77K | $404.00K | -$34.00K | 0.93x | N/A |
| 2019 | $762.64K | $463.00K | -$609.00K | 1.65x | N/A |
| 2020 | $1.15 Million | $489.00K | -$816.00K | 2.35x | N/A |
| 2021 | $577.65K | $1.53 Million | -$1.45 Million | 0.38x | N/A |
| 2022 | $366.22K | $1.62 Million | -$2.07 Million | 0.23x | N/A |
| 2023 | $74.38K | $2.18 Million | -$2.00 Million | 0.03x | N/A |
| 2024 | $83.06K | $2.19 Million | -$1.44 Million | 0.04x | N/A |
| 2025 | $105.71K | $4.11 Million | $1.00K | 0.03x | 105.71x |
Competitor Companies of RUA by Market Capitalization
Companies near Rua Life Sciences PLC in the global market cap rankings as of May 5, 2026.
Key companies related to Rua Life Sciences PLC by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #145 globally with a market cap of $152.22 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #211 globally with a market cap of $111.32 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #229 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (XETRA:2M6): Ranked #236 globally with a market cap of $101.71 Billion USD ( €87.00 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #145 | Abbott Laboratories | NYSE:ABT | $152.22 Billion | $87.54 |
| #211 | Stryker Corporation | NYSE:SYK | $111.32 Billion | $290.88 |
| #229 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | XETRA:2M6 | $101.71 Billion | €67.76 |
Rua Life Sciences PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Rua Life Sciences PLC's market cap moved from $203.88K to $ 147.24K, with a yearly change of -6.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX147.24K | +39.29% |
| 2025 | GBX105.71K | +27.27% |
| 2024 | GBX83.06K | +11.68% |
| 2023 | GBX74.38K | -79.69% |
| 2022 | GBX366.22K | -36.60% |
| 2021 | GBX577.65K | -49.67% |
| 2020 | GBX1.15 Million | +50.50% |
| 2019 | GBX762.64K | +104.04% |
| 2018 | GBX373.77K | +16.47% |
| 2017 | GBX320.91K | +112.50% |
| 2016 | GBX151.02K | -25.93% |
| 2015 | GBX203.88K | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Rua Life Sciences PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $147.24K USD |
| MoneyControl | $147.24K USD |
| MarketWatch | $147.24K USD |
| marketcap.company | $147.24K USD |
| Reuters | $147.24K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast… Read more